A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action and evolution.
mutagenicity
Two months ago, there was a mad rush to get the two oral antiviral pills approved to treat COVID-19. Pharmacies often ran out of these drugs within hours of delivery. Now, no one wants them. What is going on?
All of a sudden we have two (provisionally) FDA-approved COVID antivirals, which will be in pharmacies soon. They are quite different. Which is best for you?